Impact on health outcomes of treating all eligible large B-cell lymphoma patients with axicabtagene ciloleucel in Portugal – A modeling approach
Open Access
- 14 August 2026
- journal article
- research article
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2150-2160
Abstract
Cancer is the main cause of premature death in Portugal, and as such, reducing preventable and premature cancer deaths is one of the main public health priorities in the coming years1. In 2020, non...Keywords
Funding Information
- Gilead Sciences
This publication has 33 references indexed in Scilit:
- Lymphoma relapse 1 year or later after immunochemotherapy in DLBCL patients: clinical features and outcomeClinical and Experimental Medicine, 2024
- Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-AnalysisTransplantation and Cellular Therapy, 2023
- Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell LymphomaCurrent Oncology Reports, 2023
- Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trialNature Medicine, 2023
- The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 TrialTransplantation and Cellular Therapy, 2022
- Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United StatesTransplantation and Cellular Therapy, 2022
- Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1Value in Health, 2022
- A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value setQuality of Life Research, 2019
- Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related ToxicitiesBioDrugs, 2018
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL studyBone Marrow Transplantation, 2015